Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cells electroporated with WT1 mRNA
- Development stage
- Unknown
- Lead developer
- Antwerp University Hospital
- Modality
- Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
This autologous dendritic cell vaccine is an investigational immunotherapy developed by the University of Campinas (UNICAMP) for the treatment of high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The therapy involves the ex vivo loading of a patient's own dendritic cells with messenger RNA (mRNA) encoding the Wilms' tumor 1 (WT1) protein via electroporation. WT1 is a zinc-finger transcription factor that is highly overexpressed in various hematological malignancies and serves as a potent tumor-associated antigen. Upon re-administration to the patient, these dendritic cells present WT1-derived peptides on their surface, thereby stimulating a targeted T-cell-mediated immune response against leukemic cells. This approach is intended as an adjuvant treatment to eliminate minimal residual disease and prevent relapse in patients with high-risk myeloid disorders.
- Other names
- WT1 mRNA-electroporated Dendritic Cell VaccineWT-1 mRNA-electroporated Dendritic Cell VaccineWT 1 mRNA-electroporated Dendritic Cell VaccineWT1-DC vaccineWT-1-DC vaccineWT 1-DC vaccine
Beyond the preview
Go deeper on autologous dendritic cells electroporated with WT1 mRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cells electroporated with WT1 mRNA.